Podcast: Gillian Woollett on the Future of Biologics - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Podcast: Gillian Woollett on the Future of Biologics


Gillian R. Woollett on The Future of Biologics

Chief Scientist at Engel & Novitt, a law firm specializing in biologic standards and public policy, Gillian R. Woollett discusses the changing landscape of biologics, biosimilars, related harmonization efforts, and more. Recorded LIVE at the USP 2011 Science and Standards Symposium, October 2011, where Woollette was a keynote speaker.
Interviewed by Angie Drakulich, senior managing editor

Related podcast with USP's Tina Morris

Related podcast with USP's Matthew van Hook

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here